WuXi Biologics has won two awards at the 2023 APAC Bioprocessing Excellence Awards (ABEA) ceremony: “Best Contract Development and Manufacturing Organization Award” and “Bioprocessing Excellence in Greater China Region Award.” This is the sixth time the company has been recognized by the ABEA. WuXi Biologics supported its clients in obtaining 123 Investigational New Drug approvals in 2022 and currently supports 17 commercial biologics and vaccines. The company has 14 drug substance manufacturing facilities and 9 drug product fill sites. Its global quality system has passed 27 regulatory inspections, and it has received multiple commercial licenses for its manufacturing clients.